GLG News by Formulary Design Experts

William FinkPresidentManaged Care Pharmacy Consultants, Inc

"Health Care Laws by Any Name Will Not Work"

June 15, 2011

You can name the health care laws "ObamaCare", "Palin Care", "Trump Care", "Huckabee Care", or any "Care" you want, but they will not work, because it is not the laws that are messed up it is the public that is messed up.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

PBMs NOT ALWAYS THE BAD GUYS

May 11, 2011

There are many articles written by attorneys explaining how they can write contracts with the PBMs in order to save their clients a great deal of money.

William FinkPresidentManaged Care Pharmacy Consultants, Inc

Does the Teva Cephalon Deal have an unknown problem?

May 3, 2011

Analysis of:Teva to acquire Cephalon in 6.8 Billion Transaction | www.glgroup.com

Teva is embarking on a new and exciting future for its "Branded Business" Teva wants to obtain the "Dollars" from PROVIGIL. Provigil is a very expensive product for Narcolepsy. The price on this product was increased over 40% (approx) a few months ago. I am a clinical pharmacist , and manage pharmacy programs for HMOs and Self Insured Employer Groups. The time is coming when payors will not be able to afford medications with out a large increase in Employees out of pocket expenses.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Rx Savings with Generic vs Branded Medications

March 28, 2011

Analysis of:Buying Brand-Name Drugs Over Generics Raises Medicaid Costs | www.bloomberg.com

With dollar shortfalls for Rx benefits, controlling drug costs is imperative. By utilizing a strict formulary of covered products, along with clear, real time messaging to the pharmacies,  the generic fill rate (GFR) will rise. With a higher GFR, savings is attained.

Keith BermanConsultantHEALTH RESEARCH ASSOCIATES

Grifols Forges Ahead With New Plant Construction; Closing of Talecris Deal Nears

February 22, 2011

Analysis of:Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) | www.prnewswire.com

Adhering closely to plans approved by the company's Board in late 2007, Grifols SA announced it will shortly start construction of a new plasma fractionation plant in Barcelona.  This facility will have an annual capacity of 1 million liters, expandable to 2 million liters.  Altogether, the company's fractionation capacity in 2014 could reach 6.3 million liters -- not including another 4.2 million liters of capacity it will add with its pending deal to acquire Talecris Biotherapeutics.

Keith BermanConsultantHEALTH RESEARCH ASSOCIATES

Talecris Deal Just Weeks Away, Grifols Forges Ahead With New Plant Construction

February 19, 2011

Analysis of:Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) | www.prnewswire.com

Adhering closely to plans approved by the company's Board in late 2007, Grifols SA announced it will shortly start construction of a new plasma fractionation plant in Barcelona.  This facility will have an annual capacity of 1 million liters, expandable to 2 million liters.  Altogether, the company's fractionation capacity in 2014 could reach 6.3 million liters -- not including another 4.2 million liters of capacity it will add with its pending deal to acquire Talecris Biotherapeutics.

Keith BermanConsultantHEALTH RESEARCH ASSOCIATES

Grifols Launches 10% IVIG, Leveling Playing Field with Baxter, CSL and Talecris

November 23, 2010

Analysis of:Grifols Announces U.S. Launch of Flebogamma DIF 10% IVIG | www.prnewswire.com

With its new Flebogamma DIF 10% IVIG product, literally overnight Grifols becomes a more formidable competitor for market leaders Baxter International, CSL and Talecris Biotherapeutics.The Barcelona-based company has done remarkably well in the outsized U.S. market with a marginally less desirable 5% IVIG product, posting recent double-digit growth.  This new high-purity 10% product instantly erases that disadvantage and positions Grifols to compete effectively for years to come.

David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.

CVS vs. Walgreen's and the latest....

June 12, 2010

As a consultant and clinical pharmacist with over 30 years experience, I am glad someone.... and in this case... Walgreen's finally woke up to fees that are insulting low and a losing proposition. It has been well established the the "average expense to dispense a prescription" (the pharmacy's actual costs including rent, payroll, overhead, etc) is in the $10 range per prescription. Why would any pharmacy sign a contract with a fee of $1.50 per prescription?

Keith BermanConsultantHEALTH RESEARCH ASSOCIATES

IVIG Researchers: Consider Using Talecris' GAMUNEX More Aggressively in CIDP

June 4, 2010

Analysis of:Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | www.ncbi.nlm.nih.gov

A new analysis of the successful Talecris-sponsored crossover trial of GAMUNEX IVIG to treat CIDP revealed that only about half of responders improved at 3 weeks, while the other half didn't respond until week 6 after a second course of IVIG.  The investigators proposed that treatment with 2 doses of IVIG every 3 weeks may be required for initial improvement in some patients.  They also made a strong case for continued maintenance IVIG therapy to achieve a maximal therapeutic response.

Bruce GoldbergPharmacistKOHLL'S PHARMACY & HOMECARE, INC

Lupin's opportunity to drop the Lotrel margin!

February 15, 2010

Analysis of:Lupin gets US FDA approval for hypertension capsules | www.pharmabiz.com

The approval of Lupin's generic Lotrel line will create one more player in a field that is currently not very crowded. Yet, don't expect the other players to not react! Generic Lotrel is currently priced relatively high compared to other multi-source hypertensive products.

Page : 1234567Next1 to 10 of 69